Artikel und Beiträge

A Eser, C Primas, S Reinisch, H Vogelsang, G Novacek, D Mould, W Reinisch

Prediction of individual serum infliximab concentrations in inflammatory bowel disease by a dashboard system

J Clin Pharmacol. 2018 Jun;58(6):790-802

 

Narula N, Kainz S, Petritsch W, Haas T, Feichtenschlager T, Novacek G, Eser A, Vogelsang H, Reinisch W, Papay P.

The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.

Aliment Pharmacol Ther. 2016 Jul;44(2):170-80.

 

Wiedermann U, Sitte HH, Burgmann H, Eser A, Falb P, Holzmann H, Kitchen M, Köller M, Kollaritsch H, Kundi M, Lassmann H, Mutz I, Pickl WF, Riedl E, Sibilia M, Thalhammer F, Tucek B, Zenz W, Zwiauer K.

Guidelines for vaccination of immunocompromised individuals.

Wien Klin Wochenschr. 2016 Aug;128 Suppl 4:337-76.

 

Eser A, Colombel JF, Rutgeerts P, Vermeire S, Vogelsang H, Braddock M, Persson T, Reinisch W.

Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.

Inflamm Bowel Dis. 2015 Oct;21(10):2247-53.

 

Eser A, Primas C, Reinisch W.

Drug monitoring of biologics in inflammatory bowel disease.

Curr Opin Gastroenterol. 2013 Jul;29(4):391-6

 

Eser A, Thalhammer F, Burghuber F, Högenauer C, Stockenhuber F, Wenisch C, Widhalm K, Reinisch W.

Probiotics for the prevention of antibiotic-induced diarrhea

Z Gastroenterol. 2012 Oct;50(10):1089-95.

 

Eser A, Papay P, Primas C, Pernicka E, Harrer M, Dejaco C, Novacek G, Lichtenberger C, Angelberger S, Kazemi L, Mikulits A, Vogelsang H, Reinisch W.

The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's disease.

Aliment Pharmacol Ther. 2012 Jan;35(2):292-9.

 

Eser A, Reinisch W

„Die Pathophysiologie von Morbus Crohn und Colitis ulcerosa“

Fakten der Rheumatologie, Vol. 4, 2012, Sonderheft: Gastrointestinale und rheumatologische Erkrankungen – eine Verwandtschaft?

 

Schmid W, Vogelsang H, Papay P, Primas C, Eser A, Gratzer C, Handler M, Novacek G, Panzer S.

Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease.

J Crohns Colitis. 2014 Jun;8(6):495-503.

 

Primas C, Novacek G, Schweiger K, Mayer A, Eser A, Papay P, Gratzer C, Angelberger S, Dejaco C, Reinisch W, Vogelsang H.

Renal insufficiency in IBD - Prevalence and possible pathogenetic aspects.

J Crohns Colitis. 2013 May 21. S1873-9946(13)00176-1.

                          

Papay P, Primas C, Eser A, Novacek G, Winkler S, Frantal S, Angelberger S, Mikulits A, Dejaco C, Kazemi-Shirazi L, Vogelsang H, Reinisch W.

Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.

Aliment Pharmacol Ther. 2012 Sep 15.

 

Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, Angelberger S, Novacek G, Mikulits A, Vogelsang H, Reinisch W.

Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases.

Eur J Clin Invest. 2011 Oct;41(10):1071-6.

 

Papay P, Hackner K, Vogelsang H, Novacek G, Primas C, Reinisch W, Eser A, Mikulits A, Mayr WR, Körmöczi GF.

High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease.

Am J Med. 2012 Jul;125(7):717.e1-8.

 

Eigner W, Wrba F, Chott A, Bashir K, Primas C, Eser A, Vogelsang H.

Early recognition of possible pitfalls in histological diagnosis of celiac disease.

Scand J Gastroenterol. 2015;50(9):1088-93. doi: 10.3109/00365521.2015.1017835. Epub 2015 Feb 19.

 

Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, Novacek G, Vogelsang H, Dejaco C, Reinisch W.

Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases.

Inflamm Bowel Dis. 2011 Jan;17(1):84-90.

 

Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW; European Crohn's and Colitis Organization (ECCO).

Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection.

Clin Gastroenterol Hepatol. 2009 Sep;7(9):981-7.

 

Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, de Miera IS, Reinisch W, Chowers Y, Moran GW; European Crohn's and Colitis Organization (ECCO).

Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection.

J Crohns Colitis. 2010 Jun;4(2):194-8. Epub 2009 Nov 22.

 

Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, Domènech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SP, Colombel JF; European Crohn's and Colitis Organisation (ECCO).

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

J Crohns Colitis. 2009 Jun;3(2):47-91. Epub 2009 Apr 26.

 

Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, Geissler K: Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro

Blood. 2003 Sep 15;102 (6):2240-2.